Q-omics provides the consensus-scored PAXBP1 profile across patient tissues and cancer cell-line models. PAXBP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PAXBP1 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, PAXBP1 protein abundance shows 27,486 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where PAXBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAXBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAXBP1 survival associations across molecular data types. PAXBP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAXBP1 RNA expression–survival associations across cancer types. High PAXBP1 expression shows unfavorable associations in ACC, LIHC, UVM, KIRC and LGG, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PAXBP1 RNA expression.
This table summarizes PAXBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PAXBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAXBP1 shows lower tumor expression in KICH and higher tumor expression in BLCA, KIRC, LIHC, COAD and STAD. The BLCA box plot shows higher PAXBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with PAXBP1 in patient tissues and cancer cell lines. In patient samples, PAXBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAXBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
